Related Experiment Video
Updated: May 27, 2026
06:16
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
[Budgetary impact analysis in health: update with a model using a generic approach]
Osvaldo Ulises Garay1, Joaquín E Caporale, Andrés Pichón-Riviere
1Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina. ugaray@iecs.org.ar
Revista Peruana De Medicina Experimental Y Salud Publica
|November 17, 2011
Summary
Budgetary Impact Analysis (BIA) estimates healthcare intervention costs for institutions. This study details a flexible spreadsheet model to assess budget impact, aiding health technology adoption decisions.
Area of Science:
- Health Economics
- Health Technology Assessment
Context:
- Budgetary Impact Analysis (BIA) is crucial for healthcare decision-making.
- BIAs inform the inclusion/exclusion of interventions in health systems.
- Existing BIAs offer a partial view of health technology consequences.
Purpose:
- Identify determinants and components of Budgetary Impact Analysis.
- Describe the development of a user-friendly spreadsheet model for BIA.
- Facilitate BIA adoption in health management across various countries.
Summary:
- This paper defines Budgetary Impact Analysis (BIA) as the estimation of net financial costs for healthcare interventions.
- It presents a versatile spreadsheet model designed to assess the budget impact of any health technology.
- The model's adaptive design caters to different user skill levels and information availability.
Impact:
- Promotes wider adoption of BIA tools in health management.
- Enhances the analysis of health technology consequences beyond partial views.
- Supports informed decision-making regarding the integration of new health technologies.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...